2021 Social Responsibility Report
Boya Bio-Pharmaceutical Group Co.Ltd(300294)
Member companies of China Resources Pharmaceutical Group
Contents
01 report description 07 protection of shareholders’ and creditors’ rights and interests
02 chairman’s speech 08 protection of employees’ rights and interests
03 company profile 09 protection of rights and interests of suppliers, customers and consumers 04 development process 10 environmental protection and sustainable development
05 corporate honor 11 social responsibility
Company outlook 12 06
Report description
Welcome to 3 Zhejiang Xinnong Chemical Co.Ltd(002942) 021 corporate social responsibility report. This report aims to truly and objectively reflect the practice of corporate social responsibility in 3 Zhejiang Xinnong Chemical Co.Ltd(002942) 021, help shareholders, employees, government, customers, partners and other stakeholders to further understand the operation of the company and have an in-depth perspective on the efforts and achievements of Boya in the practice of sustainable development. Time range: from January 1, 2021 to December 31, 2021, some contents are beyond the above time range. Organization range: Boya Bio-Pharmaceutical Group Co.Ltd(300294) consolidated report range is the entity. Data Description: the financial data in the report is extracted from the 3 Zhejiang Xinnong Chemical Co.Ltd(002942) 021 annual report, and other data are from the company’s internal, system or sorted according to the annual reports of previous years. In case of any discrepancy between relevant statements or data and the annual report, the annual report shall prevail. Description: for the convenience of expression and reading, the scope of organization is represented by ” Boya Bio-Pharmaceutical Group Co.Ltd(300294) ,” Boya “,” company “or” we “in this report. Access: This report is published in both paper and electronic forms. The electronic version can be found on the official website of the company and the official website of cninfo.com（ http://www.china-boya.com./ ; http://www.cn.info.com.cn./new/index ）Consult.
Chairman’s speech
2021 is the 100th anniversary of the founding of the Communist Party of China. Boya Bio-Pharmaceutical Group Co.Ltd(300294) has also gone through 28 years in the cause of transmitting love and life. We are on the new journey of building a modern socialist country with Chinese characteristics, Boya Bio-Pharmaceutical Group Co.Ltd(300294) adhere to facing the world’s scientific and technological frontier, the main economic battlefield, major national needs and people’s life and health, further consolidate the foundation, innovate, explore, change and make breakthroughs, and constantly promote enterprises to achieve new results in high-quality development on the new journey.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) adhere to the trend of innovation, drive the development of enterprises, and constantly explore and make progress in the field of blood products. We attach great importance to scientific and technological innovation. Guided by clinical needs, we organize and hold special seminars on innovation and R & D, actively explore and layout cutting-edge technologies and processes, and are committed to providing more varieties, more quantities and better quality blood products for the society. The human prothrombin complex declared by the company successfully passed the acceptance of new products; Von Willebrand factor and intravenous human immunoglobulin (10%) obtained the notice of approval for drug clinical trial; Human coagulation factor Ⅷ successfully passed the on-site and clinical verification; The company made layout in advance, actively developed the fourth generation of Jingbing, and completed the basic process research of trace protein products. In order to take the initiative in the future market competition, we actively promote the implementation of blood products intelligent factory project in line with EU standards, and plan ahead for capacity expansion, standard improvement and digital intelligence transformation.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) adhere to management empowerment, promote business improvement, and continuously improve quality and efficiency in integrated development. Taking the opportunity of China Resources pharmaceutical’s acquisition of Boya Bio-Pharmaceutical Group Co.Ltd(300294) to build a blood products platform for the big health sector, we introduced 6S strategic management system, 5C value management system and 7C party building management system, scientifically planned the enterprise’s strategic positioning, main direction and business structure, and promoted the improvement of management. We build a “full cycle professional” ecological supply chain system from plasma collection to clinical use, salute life with professionalism, convey love and life, and escort the life safety of patients. We initiated the academic promotion mode of blood products marketing 4.0, and built the first professional academic promotion team of blood products in China to provide professional academic services for solving clinical pain points and standardizing medication, so as to reassure hospitals, doctors and patients. At the same time, Tunchang plasma station was approved with the permit for plasma collection, and Yangcheng plasma station was approved with the approval for setting up plasma collection station. Boya Bio-Pharmaceutical Group Co.Ltd(300294) ushered in the 14th plasma collection station.
Chairman’s speech
Boya Bio-Pharmaceutical Group Co.Ltd(300294) adhere to “people-oriented”, work hand in hand with investors, employees, customers, partners and other stakeholders for win-win cooperation, jointly pursue the cause of health and achieve common sustainable development. Today, in the face of the uncertain factors brought by the repeated epidemic situation, Boya Bio-Pharmaceutical Group Co.Ltd(300294) still does professional things with professional heart and devotes itself to the research and production of anti epidemic drugs. From caring students to parents’ support, from targeted poverty alleviation to rural revitalization, from earthquake relief to fighting the epidemic, Boya Bio-Pharmaceutical Group Co.Ltd(300294) charged ahead. In the process of constantly broadening their own development path, they always return to the society and serve the society with a high sense of responsibility, and work hard in the field of social public welfare with practical actions.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) prepare and release the first social responsibility report to truly disclose the performance of the company in economic, environmental and social aspects. This report is dedicated to the stakeholders who care about Boya Bio-Pharmaceutical Group Co.Ltd(300294) , corporate social responsibility, and sincerely hope to work with you to the future and start again! As the blood products platform of China Resources health sector, Boya Bio-Pharmaceutical Group Co.Ltd(300294) will continue to take “delivering love and life” as the mission, take “becoming a world-class blood products enterprise” as the vision, and take the spirit of China Resources as the guidance, focus on the main business, deepen the transformation, gather the driving force of industry development, gather the joint force of high-speed development, and make unremitting efforts to protect human health, improve the quality of life and create a better life!
Signature of chairman:
Boya Bio-Pharmaceutical Group Co.Ltd(300294) , formerly known as Jiangxi Boya Bio-Pharmaceutical Group Co.Ltd(300294) Pharmaceutical Co., Ltd., was founded in 1993. It is a comprehensive pharmaceutical industry group focusing on blood products business and integrating biochemical drugs, chemical drugs and API. It is headquartered in Fuzhou City, Jiangxi Province, with outstanding people. Its stock is simply called Boya Bio-Pharmaceutical Group Co.Ltd(300294) .
On November 25, 2021, China Resources pharmaceutical restructured Boya Bio-Pharmaceutical Group Co.Ltd(300294) to become the controlling shareholder Boya Bio-Pharmaceutical Group Co.Ltd(300294) has 6 member enterprises and 14 plasma collection stations. Its products are distributed in Jiangxi, Guangdong, Jiangsu, Sichuan, Beijing, Guizhou and Hainan. The products include blood products, diabetes and anti infection chemicals, biochemical drugs, etc., with over 90 varieties and nearly 200 specifications. The core product Human Fibrinogen products yield and market share are in the leading position in China. The company is one of the fastest growing blood products enterprises in China in recent ten years.
The company is a national high-tech enterprise and national enterprise technology center. It has established Jiangxi blood products engineering research center and postdoctoral research workstation, has more than 100 authorized patents, and has carried out extensive cooperation with well-known drug R & D institutions and universities at home and abroad in technical exchange and product R & D. The company has won the top 100 listed companies of Forbes China, the May Day Labor award of Jiangxi Province, the first prize of the scientific and technological progress award of Jiangxi Province, the Jinggang quality nomination award of Jiangxi Province, the Harmonious Labor Relations Award of Jiangxi Province, the advanced enterprise in the targeted poverty alleviation action of “thousands of enterprises helping thousands of villages” in Jiangxi Province, the honorary unit of Red Cross humanitarian relief in Jiangxi Province, the enterprise contributing to the fight against epidemic in Jiangxi Province and other honorary awards.
development history
Acquisition of Guangzhou Fuda 2021 China Resources Pharmaceutical Holdings
U Guangzhou Fuda University: positioned as a large-scale and professional dealer of blood products, November 25, 2017 u 2021, China Resources pharmaceutical restructuring Boya Bio-Pharmaceutical Group Co.Ltd(300294) became the controlling shareholder of Boya Xinhe pharmaceutical.
U positioned as high-end small molecule chemical API 2014
Professional manufacturer integrating with preparation
GEM Listing 2012
U in 2007, the controlling shareholder was changed to Shenzhen gaotejia investment group. U in 2009, Boya production base was relocated to Fuzhou high tech Zone
U on March 8, 2012, Shenzhen Stock Exchange was listed on the gem
The company was established in 1993
U the non-public offering of shares was completed by Jiangxi Provincial Department of health and Fuxin 2018
The state municipal health bureau and Linchuan District u completed a non-public offering of shares to raise 1 billion yuan. The Health Bureau jointly funded the establishment of Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) pharmaceutical industry in 2015 and built a 1000 ton international standard intelligent factory
Formerly known as the blood u system in the center of Fuzhou, it is specialized in biochemical medicine
station
Acquisition of Guizhou Tian’an pharmaceutical manufacturer
2013 u
Diabetes treatment and chronic diseases.
Professional service provider
2001 joint stock reform
Company honor
20132014 Forbes Chinese edition top 100 Chinese potential listed companies 2014 top 50 Chinese listed companies on GEM 2015 China’s top 100 listed companies most respected by investors 2016 China’s top 150 listed companies with Taurus value investment 2017 top 10 pharmaceutical companies with the most investment value Jiangxi provincial first prize for scientific and technological progress 2018 China’s top 20 biomedical enterprises, Among the top 50 companies listed on GEM in 2018, the advanced enterprise of targeted poverty alleviation action of “thousands of enterprises helping thousands of villages” in Jiangxi Province won the “golden bull most valuable investment Award” successively from 2018 to 2019. In 2019, it was recognized as a national high-tech enterprise, the national enterprise technology Center won the Jiangxi anti epidemic contribution Enterprise Award in 2020, the nomination award of the third Jinggang Quality Award in Jiangxi Province, and the honorary unit of humanitarian assistance of Jiangxi Red Cross Society in 2021
Company honor
Jiangxi model enterprise with harmonious labor relations 2021 Jiangxi top 100 enterprises (84) Guangdong advanced grass-roots party organization tax credit class a honorary certificate 2020 Wudang District “hundreds of enterprises help thousands of households” honorary certificate 2020 covid-19 outstanding contribution to the prevention and control of pneumonia epidemic honorary certificate the batching class of the production department won the “worker pioneer” certificate Guizhou integrity demonstration enterprise plaque Guizhou integrity demonstration enterprise certificate 2021 Guizhou Green
